NCT07521137

Biweekly Long-term Occidiofungin Study for Suppression of Mycotic Recurrence

A Randomized, Double-Blind, Placebo-Controlled Phase 2a Study Evaluating the Safety, Tolerability, and Efficacy of OCF001 Intravaginal Gel in Women With Acute Vulvovaginal Candidiasis

• Status: Not Yet Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 36 (estimated)
• Sponsor: Sano Chemicals Inc · Industry
• Sex: Female
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

A Randomized, Double-Blind, Placebo-Controlled Phase 2a Study Evaluating the Safety, Tolerability, and Efficacy of OCF001 Intravaginal Gel in Women with Acute Vulvovaginal Candidiasis

Conditions

• Candidiasis, Vulvovaginal

Interventions

Type	Name	Description
DRUG	OCF001 Intravaginal Gel	OCF001 is an antifungal antibiotic that is formulated in a water-miscible viscous gel at concentrations of 0.150 mg / g of gel.
DRUG	Placebo Gel	Placebo (Gel formulation without OCF)

Timeline

• Start date: 2026-04-20
• Primary completion: 2026-12-31
• Completion: 2026-12-31
• First posted: 2026-04-09
• Last updated: 2026-04-14

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study